Présentation de l'entreprise
Niagen Bioscience, Inc. operates within the healthcare sector as a biotechnology firm dedicated to developing healthy aging products through its Consumer Products, Ingredients, and Pharmaceutical segments. The company specializes in manufacturing and distributing finished dietary supplement products that incorporate its proprietary ingredients directly to consumers. As of the latest data, the entity employs a workforce of 117 individuals and maintains a market capitalization of $368.37 million. With annual revenue reaching $129.42 million, these financial figures indicate that Niagen has established a significant operational footprint within the biotechnology industry, positioning it as a mid-sized player with substantial market valuation relative to its revenue base.
Santé financière
The company reported a total revenue of $129.42 million over the trailing twelve months, generating net income of $17.38 million and an EBITDA of $15.08 million. The disparity between the $129.42 million revenue and the $17.38 million net income reveals a cost structure where operating expenses, taxes, and interest costs consume approximately 86.6% of top-line revenue before reaching the bottom line. Free cash flow stands at $4.88 million, which demonstrates that the company generates positive cash from operations sufficient to cover capital expenditures and maintain financial flexibility for strategic initiatives. Operating margins are analyzed through three distinct layers: a gross margin of 64.3%, an operating margin of 6.2%, and a profit margin of 13.4%, indicating that while the core production costs are well-controlled, operational overheads significantly impact pre-tax profitability. The balance sheet holds $64.64 million in cash against only $2.82 million in debt, supported by a debt-to-equity ratio of 3.68, suggesting a capital structure that is heavily weighted toward equity financing rather than leverage. Short-term liquidity is robust, evidenced by a current ratio of 4.86, which implies the company possesses more than four times the current assets necessary to settle its short-term liabilities. Return on equity is calculated at 28.3% and return on assets at 10.2%, metrics that collectively reveal management's effectiveness in generating returns on shareholder capital and utilizing the company's asset base to produce earnings.
Évaluation de la valorisation
Valuation metrics for Niagen Bioscience, Inc. show a trailing P/E ratio of 23.00 compared to a forward P/E of 14.38. The significant difference between these two figures implies that the market expects earnings to decline substantially in the near future, as the forward multiple is notably lower than the historical average. The price-to-book ratio stands at 4.80, indicating that the market is pricing the company at a substantial premium of nearly five times its net asset book value. Alternative valuation indicators include a price-to-sales ratio of 2.85 and an EV/EBITDA of 20.38, which suggest investors are willing to pay a high multiple relative to both sales and earnings before interest, taxes, depreciation, and amortization. Regarding price momentum, the stock traded between a 52-week low of $4.16 and a high of $14.69, with the current price sitting at a level that reflects significant volatility within this specific trading range. The stock exhibits a beta of 2.23, meaning its price volatility is more than double that of the broader market, indicating high sensitivity to general market movements.
Growth & Income
The company's revenue growth year-over-year is 16.2%, whereas earnings growth year-over-year stands at -41.6%. This divergence indicates that earnings are currently growing much slower than revenue, or in this case, contracting significantly while sales expand, which implies rising costs or non-recurring expenses are impacting profitability more severely than top-line performance. As Niagen Bioscience, Inc. does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the company reinvests all of its earnings back into the business for research, development, and growth rather than distributing income to shareholders. This absence of a dividend yield aligns with the company's growth-oriented strategy, where capital retention is prioritized to fund its proprietary aging technology and product expansion. Overall, the growth and income profile is characterized by expanding sales volume but facing significant pressure on earnings margins, with no current cash return to shareholders via dividends.